Patients with systemic autoimmune rheumatic diseases, COVID-
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Patients with systemic autoimmune rheumatic diseases and COVID-19 may be at greater risk for hospitalization, ICU admission, acute renal failure and venous thromboembolism, according to data published in Arthritis & Rheumatology.

Patients living with systemic autoimmune rheumatic diseases (SARDs) continue to be concerned about risks of severe COVID-19 outcomes.

Using a large multi-center electronic health record network, researchers conducted a comparative cohort study of patients with SARDs diagnosed with COVID-19 (identified by diagnostic code or positive molecular test) versus non-SARD comparators with COVID-19, matched by age, sex, race/ethnicity, and body mass index (primary model) and comorbidities and health care utilization (extended model). Thirty-day outcomes were assessed, including hospitalization, intensive care unit (ICU) admission, mechanical ventilation, acute renal failure requiring renal replacement therapy (ARF), ischemic stroke, venous thromboembolism (VTE), and death.

Results:
-- Researchers initially identified 2,379 SARD patients with COVID-19 and 142,750 comparators.

-- In the primary matched model (2,379 SARD patients and 2,379 matched non-SARD comparators with COVID-19), SARD patients had significantly higher risks of hospitalization, ICU admission, ARF, and VTE versus comparators but did not have significantly higher risks of mechanical ventilation or death.

-- In the extended model, all risks were largely attenuated except risk of VTE.

Conclusively, SARD patients with COVID-19 may be at higher risk of hospitalization, ICU admission, ARF, and VTE versus matched comparators. These risks may be largely mediated by comorbidities, except for risk of VTE.

Source: https://onlinelibrary.wiley.com/doi/10.1002/art.41619
Like
Comment
Share